CEOCFO Magazine, PO Box 340
Palm Harbor, FL 34682-0340
Phone: 727-480-7070



Business Services | Solutions
Medical | Biotech
Cannabis  | Hemp
Banking | FinTech | Capital
Government Services
Public Companies
 Industrial | Resources

Clean Tech  
Global | Canadian

Lynn Fosse, Senior Editor

Steve Alexander, Associate Editor

Bud Wayne, Marketing
& Production Manager

Christy Rivers - Editorial Associate



Doseology Sciences: Harnessing the Power of Mushrooms for Lasting Human Health

Maryam Marissen





Maryam Marissen

(236) 349 – 0064

Interview conducted by:

Lynn Fosse, Senior Editor

CEOCFO Magazine

Published – February 28, 2022

CEOCFO: Ms. Marissen, what is the overall idea behind Doseology Sciences, Inc.?

Ms. Marissen: Doseology is an innovative and sustainable life sciences company. We work in the space of wellbeing and mental health, developing modalities and programs that are designed to help real people heal, inside and out.

While we do study functional mushrooms — and currently offer products rich in adaptogenic ingredients like turkey tail, reishi, and cordyceps — our primary focus is psychedelics.

You’ve probably heard that psilocybin is showing massive potential as a treatment option for patients failed by traditional therapies, especially in the space of mental health. Our goal is to harness that power, and foster an alternative route to wellness that boasts benefits for individuals — and society at large.

CEOCFO: Why the decision to focus in that area?

Ms. Marissen: That’s a great question. The truth is that we only arrived here by looking to the past.

Psychedelics have been used in traditional medicinal and religious practices for thousands of years, coming up over and over in the space of “mental health” — even when no one was calling it that.

Unfortunately, the progress we were making was largely derailed in the sixties when the US federal government launched the War on Drugs, an initiative that lumped several substances together, overlooking the very real potential some of them showed.

The result? We missed out on years of ground-breaking research — and people who could have really benefited from these treatments had to go without.

Looking back, it’s pretty clear that the perspective here was too black and white, and that there’s a greater purpose to be met. Doseology plans to pick up where the research left off and make real change, particularly for people with conditions like anxiety and depression that aren’t responding to conventional treatments.  

CEOCFO: What was the starting point for you and where have you gotten so far?

Ms. Marissen: For me, this journey was really personal.

About five years ago, I was in the depths of my own struggle with mental health. I came to Canada as a refugee from Iran, which meant a lot of upheaval and change in my early years — experiences that made a profound impression. Unsurprisingly, I carried that weight well into adulthood.

I struggled to reconcile my childhood trauma and instability, and faced what seemed like an impossible battle when it came to my mental health. It was this turbulence, and persistent depression that led me down my unconventional path.

I’m proactive by nature, and went to work researching alternative treatments that had shown results in cases like mine. Early on, I stumbled upon ketamine and was immediately fascinated. But back then, ketamine therapy was not very common — and pretty much non-existent in Canada. Most of the work that was being done in this space was happening at select clinics in the United States. So, that whole pursuit got put on hold.

Luckily, about three years ago, I was introduced to psilocybin, or the psychedelic you might know simply as “magic mushrooms.” I learned that psilocybin could be used in very small quantities — or microdosed — to improve mental health. It only took one experience for me to see a profound change in myself. The positive effects were immediate, and lasted for a few days. I can’t begin to describe my relief. I have never really been into alcohol, or cannabis, or any recreational drugs, so for me, this was really only about my health.

It felt like a shot in the dark… but I couldn’t ignore how much it helped. I really started to look at it and wonder… is this a practice that could be made more accessible, and create change for those who struggled like I did? I dove into the research to learn everything I could about where we are with psychedelics today. I saw how they’d been used to heal real people and I wanted to be part of the efforts to help.

CEOCFO: What are you working on right now?

Ms. Marissen: Our company is vertically integrated, and we’re focusing on a few different areas.

As we speak, we’re in the process of getting our Dealer’s License from Health Canada. This would allow us to cultivate, purify, study, and eventually supply medical grade psilocybin to patients — once it’s been legalized, anyway — and for further research, clinical trials, and R&D. But that’s just one facet of our business.

On the other side, we are initiating our own R&D focus. Our primary goal is to optimize the profile of compounds that we believe would be beneficial, and increase their safety and stability so we can deliver it in a predictable, consistent way. As part of this process, we have to look at all the variables that are currently a challenge with something like this — including dosage, and the onset and duration of psilocybin impacts.

We are also developing our own proprietary program for clinical practice. It would allow us to target patients that we believe have a unique and increased need for medically supervised treatment and ongoing support. The end goal here is an all encompassing approach that employs psychotherapy and other supportive services for maximum result.

The last pillar of our business centers around nootropics, including functional mushrooms like turkey tail and reishi. While their application is different from psilocybin, these powerful plants have shown huge potential when it comes to cognitive clarity, the reduction of inflammation, and our ability to adapt to daily stress.

CEOCFO: Would you tell us about the products you have available today at Doseology?

Ms. Marissen: Sure would. Right now, consumers can easily get their hands on our non-psychedelic nootropics line. It features products in both tincture and powder form. Each formula is based around one key mushroom, and has its own indication and profile.

To make this line even more effective, we’ve added a second, and sometimes third, plant-based, health-promoting ingredient. This is called stacking and it allows us to optimize the performance and results of each formula.

CEOCFO: How is business?

Ms. Marissen: Great! Sure, it’s a new industry — but it’s also a burgeoning one.

We have so much that we need to cover. There is extraordinary potential here and I really think the outlook is amazing. There is so much movement, and so much interest. We are opening our minds, and public awareness is really driving the need and demand for products and services like these.

CEOCFO: How do you reach out to potential customers?

Ms. Marissen: Right now, we have a robust marketing program. Our team is incredible, and has a wealth of experience working with high-end brands and on the consumer side of products.

We came out of the gate focused on the nootropics, but are working to expand our reach — and our message — in the United States and Canada. Consumer education is vital in this field, and it’s important to us that the information is accessible and prominent. This is something we’re working on around the clock.  

We also want to make sure we are a leading name when it comes to clinical practice, and that starts with our clinical patient group. When psychotherapy, psilocybin, and ketamine therapy come up, we want Doseology to be top of mind. It’s important to us that people see our brand not only as a leading source of product and expertise, but as their trusted premium care provider.     

CEOCFO: Are there products that are not getting the attention you think they should?  

Ms. Marissen: When it comes to psychedelics, we have a long way to go to build real public awareness.

I think that there is a general sense of curiosity and interest, but there is still a lot of education that needs to happen. We need to increase accessibility and information in order to make real change and solidify our place in the broader market.

For us, this is a matter of reframing public perception, and letting people know that our practices are scientific, safe, and effective.

CEOCFO: You were appointed CEO recently. How did that come about?

Ms. Marissen: My background is in consumer product marketing, private clinic services, and public relations and advocacy. I first started in this space about a year ago, when I launched my bio-pharma startup in partnership with another researcher. Its focus was psilocybin and other psychedelic molecules. We started to explore how these treatments could be improved in terms of their safety, and delivery.

Ultimately, that relationship didn’t work out… but I knew I had to move forward regardless because this work is so important to me. With Doseology, I found the right fit. We connected over our objectives, mission, and passion. I joined the company first as a consultant in November, and by January was announced as CEO.    

CEOCFO: How do you reach out to potential investors? How do you gain traction in that arena?

Ms. Marissen: We prioritize communication, transparency, and connection. It’s important to us that both potential and current investors know our company is continuously working on developing our model on all fronts.

Since I came on board, we’ve doubled down on news releases and email correspondence. We are also rebuilding our investor website to bolster communication around our areas of focus, and what’s up next.

We are looking forward to rolling out a lot of new information over the coming months.

CEOCFO: What are some of the challenges in growing mushrooms?

Ms. Marissen: Good question! There are plenty.

This is particularly fascinating because in nature, they grow effortlessly but when you are trying to cultivate them within a facility, there are definitely nuances and sensitivities to consider.

We need to ensure production is sterile and that we’re capturing the best strains, optimizing them, and running checks on them to produce a product that is safe, consistent, and the best it can be.

CEOCFO: Why is this the right time for this type of product? Why are people ready health wise for this now?

Ms. Marissen: I’d say we’re beyond the right time — and this is seriously overdue.

When it comes to mental health and pharmacology, we really haven’t had the kind of innovation we need over the last 40 years. There is a huge gap between patient requirements and effective solutions, and it’s created a massive, unnecessary burden that impacts everyone we meet.

Obviously, this is a sore point we’re feeling particularly intensely in the face of COVID-19, and an increase in anxiety, depression, suicide and overdose. The solutions that are available on the pharmacology side fail to adequately address the entire patient population, and they leave huge gaps when it comes to people who are particularly vulnerable or resistant to treatment.

Even worse, they overlook the root causes of these disorders. I think it’s time that we ask ourselves whether we’re just managing symptoms — or actually helping people get better for good.

CEOCFO: Put it together for our readers; potential customers, potential partners, potential investors. Why does Doseology Sciences Inc. stand out in all of those arenas?

Ms. Marissen: We are small but seriously experienced. What sets us apart is our team, our passion, and our skill level.

We offer a fresh take despite our size, and are poised to make change in areas other brands overlook. We are focusing on some key elements that aren’t yet on the radar in terms of IP and our clinical approach.  

Beyond that, we’re a life sciences company. Our mission is to help people who are hurting heal, optimize their health, and live the best life that they can — no matter the circumstances they’ve been dealt.

Doseology | Maryam Marissen | Medicinal Mushrooms Products | psychedelic mushrooms | CSE: MOOD | Doseology Sciences: Harnessing the Power of Mushrooms for Lasting Human Health | CEO Interviews 2022 | Medical Companies | Public Company | Global Companies | grow kits / clinics / functional mushrooms / adaptogens / health / wellness, Doseology Press Releases, News, Twitter, Facebook, Linkedin, Instagram, Youtube, TickTok

“Our mission is to help people who are hurting heal, optimize their health, and live the best life that they can — no matter the circumstances they’ve been dealt.”
Maryam Marissen